Release Date: December 27, 2017
Expiration Date: December 27, 2018

Expected time to complete this activity as designed: 45 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, participants will hear key highlights taken from of a select group of abstracts which focused on some of the most impactful data in Hodgkin lymphoma (HL), presented at the 2017 American Society of Hematology (ASH) 59th Annual Meeting. Leading experts in the field of HL will share their insights on a variety of abstracts, covering topics including, but not limited to: PET imaging as a predictor of outcomes in advanced-stage cHL, a report on the phase 3 trial looking at the possibility of treatment reduction in relation to negative interim PET findings and the anticipated phase 3 ECHELON trial results.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with Hodgkin lymphoma (HL)
• Describe expert faculty perspectives on key clinical trial data for novel therapies and treatment strategies in HL
• Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in HL

Agenda

Early Interim PET in Patients with Advanced-Stage HL Treated within the Phase 3 GHSG HD18 Study – Peter Borchmann, MD

Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma – Robert W. Chen, MD

Phase 2 Checkmate 205 Study Looking at Nivolumab for Newly Diagnosed Advanced-Stage cHL and Outcomes in Patients with Relapsed/Refractory cHL – Jonathon B. Cohen, MD, MS

Positive Phase 3 Data from ECHELON 1 Clinical Trial Comparing A+AVD as Frontline Therapy in Previously Untreated Advanced HL – Joseph M. Connors, MD, FRCPC

Studies That Will Impact or Shape Treatment of HL in 2018 – Matthew Matasar, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 27, 2018. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Peter Borchmann, MD
Assistant Medical Director
Department of Hematology/Oncology
University Hospital of Cologne
Cologne, Germany

Dr. Peter Borchmann is Assistant Medical Director in the Department of Hematology/Oncology at the University Hospital of Cologne where he is Head of the Lymphoma Program. He is also Co-Chairman of the German Hodgkin Study Group (GHSG) and responsible for development of investigator initiated clinical studies in Hodgkin lymphoma (HL). Dr. Borchmann’s scientific focus within the GHSG is to optimize the treatment of advanced stage HL patients and elderly patients. He is also the leader of the working group “Survivorship” (http://www.ghsg.org).

Robert W. Chen, MD
Associate Professor of Medicine
Associate Director, Toni Stephenson Lymphoma Center
Department of Hematology/Hematopoietic Cell Transplantation
City of Hope National Medical Center
Duarte, California

Dr. Robert Chen received his medical degree from Northwestern University Medical School Chicago, Illinois. He completed his internal medicine residency at the University of Colorado Health Sciences Center in Denver, and his hematology/oncology fellowship at the University of Colorado Cancer Center, Aurora, Colorado. Dr. Chen is an Associate Professor and Associate Director of the Toni Stephenson Lymphoma Center in the Department of Hematology/Hematopoietic Cell Transplantation, City of Hope (COH) National Medical Center in Duarte, California. At COH, Dr. Chen is also the Co-Leader of the Lymphoma Disease and Early Phase Therapeutic Disease Teams.

Dr. Chen holds memberships in the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, and the Rocky Mountain Oncology Society (Colorado), among others. In addition, he is an NCCN Hodgkin lymphoma panel member, on the SWOG Lymphoma Working Group, and is associate chair, Cedar Park Regional Medical Center (CPRMC). He is a reviewer for the Journal of Clinical Oncology, Blood, Biology of Bone and Marrow Transplantation, Oncogene, Plos, Leukemia Research, Lymphoma and Leukemia, Clinical Lymphoma and Myeloma, as well as the American Society of Hematology.

Jonathon B. Cohen, MD, MS
Assistant Professor
Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, Georgia

Dr. Jonathon Cohen received his medical degree at the University of Florida College of Medicine. He completed a residency in internal medicine and fellowship in hematology and medical oncology at The Ohio State University in Columbus, Ohio. During his fellowship, he also completed a master’s degree in medical science, gathering additional training in the conduct of clinical and translational research. Dr. Cohen is an Assistant Professor in Hematology and Medical Oncology at the Emory University School of Medicine in Atlanta.

Dr. Cohen’s clinical focus is on the treatment of Hodgkin and non-Hodgkin lymphoma, where he manages both newly diagnosed patients as well as those requiring stem cell transplantation and treatment for relapsed disease. His research focus includes the clinical investigation of lymphoma, where he aims to identify prognostic markers and designs clinical trials with novel agents for patients with relapsed disease. Dr. Cohen has been recognized as a promising young investigator as evidenced by his selection to participate in the ASCO/AACR Methods in Clinical Cancer Research workshop and the American Society of Hematology Clinical Research Training Institute.

Joseph M. Connors, MD, FRCPC
Clinical Professor of Medicine
Medical Oncologist, BC Cancer Agency
Clinical Director, BC Cancer Centre for Lymphoid Cancer
University of British Columbia
Vancouver, British Columbia, Canada

Dr. Joseph Connors received his medical degree from Yale University. He completed his internal medicine residency and chief residency at the University of North Carolina in Chapel Hill, and his medical oncology fellowship at Stanford University. He is a Clinical Professor of Medicine at the University of British Columbia, and serves as a Medical Oncologist, BC Cancer Agency, and Clinical Director of the BC Cancer Centre for Lymphoid Cancer.

Dr. Connors serves as a member of the executive committee of the Hematology Site Group for the Canadian Cancer Trials Group, and served previously as a Councilor of the American Society of Hematology. He has published more than 250 peer-reviewed scientific articles addressing various aspects of research into lymphoid cancers. Dr. Connors is best known for his clinical investigations into the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemias and multiple myeloma.

Matthew Matasar, MD
Lymphoma and Adult BMT Services
Director, Lymphoma Survivorship Clinic
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Matthew Matasar, a board-certified medical oncologist/hematologist, received his medical degree from Harvard University. His internal medicine training was completed at Columbia Presbyterian, where he earned a master’s in biostatistics, and served as chief resident. His fellowship training was in medical oncology at Memorial Sloan Kettering Cancer Center, where he subsequently joined faculty on the Lymphoma and Adult BMT Services. Dr. Matasar is also the Director of the Lymphoma Survivorship Clinic, where he focuses on the management of long-term survivors of Hodgkin and non-Hodgkin lymphoma. As a member of the lymphoma and BMT services, his research is aimed to explore the management of aggressive lymphomas, focusing on improving outcomes in relapsed but curable patients using novel therapy and stem cell transplantation techniques. His primary research interest is in developing a research program to better understand the optimal care of lymphoma survivors, focusing on reducing the risk and improving the management of late effects of chemotherapy and radiation therapy.

Accreditation

CME CREDIT Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.75 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-182-H01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Peter Borchmann has received honoraria as a consultant from Celgene Corporation, F. Hoffmann-La Roche Ltd, Novartis AG, and Takeda Oncology, as well as formal advisory activities from Bristol-Myers Squibb Company and Novartis. He has received grant support related to research activities from Celgene, Novartis, and Takeda Oncology.

Dr. Robert Chen has received honoraria related to speakers’ bureau activities from Genentech, Inc., Merck & Co., and Seattle Genetics, Inc., as well as consultant fees from Bristol-Myers Squibb Company, Merck, Pfizer Inc., Pharmacyclics, Inc., and Seattle Genetics.

Dr. Jonathon Cohen has received honoraria as a consultant from Celgene Corporation, Extera, Genentech, Inc., and Pharmacyclics, Inc. He has received grant support related to research activities from AbbVie Inc., Bristol-Myers Squibb Company, Seattle Genetics, Inc., and Takeda Oncology.

Dr. Joseph Connors has received grant support related to research activities from Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Cephalon, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genentech, Inc., Janssen Pharmaceuticals, Inc., NanoString Technologies, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., and Seattle Genetics, Inc.

Dr. Mathew Matasar has disclosed no relevant financial relationships.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected].

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.